163 related articles for article (PubMed ID: 36290871)
41. The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
Harris PE; Zhernosekov K
Front Endocrinol (Lausanne); 2022; 13():941832. PubMed ID: 36387893
[TBL] [Abstract][Full Text] [Related]
42. Targeted antisense radiotherapy and dose fractionation using a (177)Lu-labeled anti-bcl-2 peptide nucleic acid-peptide conjugate.
Liu D; Balkin ER; Jia F; Ruthengael VC; Smith CJ; Lewis MR
Nucl Med Biol; 2015 Sep; 42(9):704-10. PubMed ID: 26081917
[TBL] [Abstract][Full Text] [Related]
43. Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Symptomatic Control of Refractory Carcinoid Syndrome.
Zandee WT; Brabander T; Blažević A; Minczeles NS; Feelders RA; de Herder WW; Hofland J
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3665-e3672. PubMed ID: 33942075
[TBL] [Abstract][Full Text] [Related]
44. The use of (68)Ga DOTATATE PET/CT for diagnostic assessment and monitoring of (177)Lu DOTATATE therapy in pituitary carcinoma.
Novruzov F; Aliyev JA; Jaunmuktane Z; Bomanji JB; Kayani I
Clin Nucl Med; 2015 Jan; 40(1):47-9. PubMed ID: 25275413
[TBL] [Abstract][Full Text] [Related]
45. PLGA nanoparticles for peptide receptor radionuclide therapy of neuroendocrine tumors: a novel approach towards reduction of renal radiation dose.
Arora G; Shukla J; Ghosh S; Maulik SK; Malhotra A; Bandopadhyaya G
PLoS One; 2012; 7(3):e34019. PubMed ID: 22442740
[TBL] [Abstract][Full Text] [Related]
46. Use of
Oliván-Sasot P; Falgás-Lacueva M; García-Sánchez J; Vera-Pinto V; Olivas-Arroyo C; Bello-Arques P
Rev Esp Med Nucl Imagen Mol; 2017; 36(2):116-119. PubMed ID: 27793633
[TBL] [Abstract][Full Text] [Related]
47. Somatostatin receptor saturation after administration of high peptide amounts of [
Siebinga H; Veerman CHAM; de Wit-van der Veen L; Stokkel MPM; Hendrikx JJMA; Aalbersberg EA
EJNMMI Res; 2022 Dec; 12(1):74. PubMed ID: 36515683
[TBL] [Abstract][Full Text] [Related]
48. [Expression of SOX11 mRNA in mantle cell lymphoma and its clinical significance].
Wang YY; Yu Z; Yi SH; Li ZJ; Li CH; Xie ZQ; Li F; Zang MR; Hao M; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2012 Jul; 33(7):556-60. PubMed ID: 22967417
[TBL] [Abstract][Full Text] [Related]
49. 4D SPECT/CT acquisition for 3D dose calculation and dose planning in (177)Lu-peptide receptor radionuclide therapy: applications for clinical routine.
Kairemo K; Kangasmäki A
Recent Results Cancer Res; 2013; 194():537-50. PubMed ID: 22918781
[TBL] [Abstract][Full Text] [Related]
50. Additional hepatic
Braat AJAT; Kwekkeboom DJ; Kam BLR; Teunissen JJM; de Herder WW; Dreijerink KMA; van Rooij R; Krijger GC; de Jong HWAM; van den Bosch MAAJ; Lam MGEH
BMC Gastroenterol; 2018 Jun; 18(1):84. PubMed ID: 29902988
[TBL] [Abstract][Full Text] [Related]
51. Striking Size Reduction of Rapidly Growing Pancreatic Neuroendocrine Carcinoma Metastatic Nodal Conglomerate After Only 2 Cycles of 177 Lu-DOTATATE.
Somoza EA; Duan H; Shaheen S; Fischer GA; Aparici CM
Clin Nucl Med; 2022 Nov; 47(11):961-962. PubMed ID: 35695695
[TBL] [Abstract][Full Text] [Related]
52. Lutetium Lu-177 Dotatate Flare Reaction.
Salner AL; Blankenship B; Dunnack H; Niemann C; Bertsch H
Adv Radiat Oncol; 2021; 6(1):100623. PubMed ID: 33490736
[TBL] [Abstract][Full Text] [Related]
53. Additional lesions detected in therapeutic scans with 177Lu-DOTATATE reflect higher affinity of 177Lu-DOTATATE for somatostatin receptors.
Mirzaei S; Bastati B; Lipp RW; Knoll P; Zojer N; Ludwig H
Oncology; 2011; 80(5-6):326-9. PubMed ID: 21791941
[TBL] [Abstract][Full Text] [Related]
54. Lutetium-177 Radiopharmeceutical Therapy Extravasation Lessons Learned.
Berry K; Kendrick J
Health Phys; 2022 Aug; 123(2):160-164. PubMed ID: 35318982
[TBL] [Abstract][Full Text] [Related]
55. Cyclin D1-negative blastoid mantle cell lymphoma identified by SOX11 expression.
Zeng W; Fu K; Quintanilla-Fend L; Lim M; Ondrejka S; Hsi ED
Am J Surg Pathol; 2012 Feb; 36(2):214-9. PubMed ID: 22251940
[TBL] [Abstract][Full Text] [Related]
56. Twins in spirit part IV - [
Brogsitter C; Hartmann H; Wunderlich G; Schottelius M; Wester HJ; Kotzerke J
Nuklearmedizin; 2017 Feb; 56(1):1-8. PubMed ID: 28138688
[TBL] [Abstract][Full Text] [Related]
57. Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience.
Delpassand ES; Samarghandi A; Zamanian S; Wolin EM; Hamiditabar M; Espenan GD; Erion JL; O'Dorisio TM; Kvols LK; Simon J; Wolfangel R; Camp A; Krenning EP; Mojtahedi A
Pancreas; 2014 May; 43(4):518-25. PubMed ID: 24632546
[TBL] [Abstract][Full Text] [Related]
58. LONG-TERM EFFECT OF
Iglesias P; Martínez A; Gajate P; Alonso T; Navarro T; Díez JJ
AACE Clin Case Rep; 2019; 5(6):e330-e333. PubMed ID: 31967064
[TBL] [Abstract][Full Text] [Related]
59. Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues.
Bodei L; Pepe G; Paganelli G
Eur Rev Med Pharmacol Sci; 2010 Apr; 14(4):347-51. PubMed ID: 20496546
[TBL] [Abstract][Full Text] [Related]
60. A comparative study of 131I and 177Lu labeled somatostatin analogues for therapy of neuroendocrine tumours.
de Araújo EB; Caldeira Filho JS; Nagamati LT; Muramoto E; Colturato MT; Couto RM; Pujatti PB; Mengatti J; Silva CP
Appl Radiat Isot; 2009 Feb; 67(2):227-33. PubMed ID: 19027307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]